PNET5MB: An international prospective trial on medulloblastoma (MB) in children older than 3 to 5 years with WNT biological profile (PNET 5 MB – LR and PNET 5 MB – WNT-HR), average-risk biological profile (PNET 5 MB -SR), or TP53 mutation, and registry for MB occurring in the context of genetic predisposition
Principal investigator: Virve Pentikäinen
HUS Helsinki University Hospital, New Childern’s Hospital